CEFTAZIDIME PANPHARMA 2 G

Riik: Iisrael

keel: inglise

Allikas: Ministry of Health

Toimeaine:

CEFTAZIDIME AS PENTAHYDRATE

Saadav alates:

PHARMALOGIC LTD

ATC kood:

J01DD02

Ravimvorm:

POWDER FOR SOLUTION FOR INJ/INF

Koostis:

CEFTAZIDIME AS PENTAHYDRATE 2 G

Manustamisviis:

I.V

Retsepti tüüp:

Required

Valmistatud:

PANPHARMA, FRANCE

Terapeutiline ala:

CEFTAZIDIME

Näidustused:

Ceftazidime Panpharma is indicated for the treatment of the infections listed below in adults and children including neonates (from birth). - Nosocomial pneumonia- Broncho-pulmonary infections in cystic fibrosis- Bacterial meningitis- Chronic supportive otitis media- Malignant otitis externa- Complicated urinary tract infections- Complicated skin and soft issues infections- Complicated intra-abdominal infections- Bone and joint infections- Peritonitis associated with dialysis in patients with CAPDTreatment of patients with bacteremia that occurs in association with, or is suspected to be associated with, any of the infections listed above.Ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.Ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing transurethral resection of the prostate (TURP).

Loa andmise kuupäev:

2022-07-31

Toote omadused

This leaflet format has been determined by the Ministry of Health and
the content thereof
has been checked and approved on August 2017
1.
NAME OF THE MEDICINAL PRODUCT
CEFTAZIDIME PANPHARMA 1 G
CEFTAZIDIME PANPHARMA 2 G
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substance per vial of powder:
Ceftazidime as Ceftazidime
pentahydrate.......................................................1 g
with sodium carbonate (118 mg per 1 g of ceftazidime)
Ceftazidime as Ceftazidime
pentahydrate.......................................................2 g
with sodium carbonate (236 mg per 2 g of ceftazidime)
List of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder for solution for injection or infusion.
White to pale yellow powder.
4.
CLINICAL INFORMATION
4.1
THERAPEUTIC INDICATIONS
Ceftazidime Panpharma is indicated for the treatment of the infections
listed below in
adults and children including neonates (from birth).
- Nosocomial pneumonia
- Broncho-pulmonary infections in cystic fibrosis
- Bacterial meningitis
- Chronic supportive otitis media
- Malignant otitis externa
- Complicated urinary tract infections
- Complicated skin and soft tissue infections
- Complicated intra-abdominal infections
- Bone and joint infections
- Peritonitis associated with dialysis in patients with CAPD
Treatment of patients with bacteremia that occurs in association with,
or is suspected to
be associated with, any of the infections listed above.
Ceftazidime may be used in the management of neutropenic patients with
fever that is
suspected to be due to a bacterial infection.
Ceftazidime may be used in the peri-operative prophylaxis of urinary
tract infections for
patients undergoing transurethral resection of the prostate (TURP).
The selection of ceftazidime should take into account its
antibacterial spectrum, which is
mainly restricted to aerobic Gram-negative bacteria (see sections 4.4
and 5.1).
Ceftazidime should be co-administered with other antibacterial agents
whenever the
possible range of causative bacteria would not fall wi